The Journal of Nuclear Medicine (JNM) Editors’ Conflicts of Interest Disclosures
Johannes Czernin, MD, editor-in-chief of The Journal of Nuclear Medicine, has indicated that he is a founder of Sofie Biosciences and holds equity in the company and in intellectual property invented by him, patented by the University of California, and licensed to Sofie Biosciences. He is also a founder and board member of Trethera Therapeutics and holds equity in the company and in intellectual property invented by him, patented by the University of California, and licensed to Triangle. He also serves on the medical advisory board of Actinium Pharmaceuticals and on the scientific advisory boards of POINT Biopharma, RayzeBio, and Jubilant Pharma; is a consultant for Amgen; No other potential conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.
Carolyn J. Anderson, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that she is on the Scientific Advisory Board of Luminphore (Berkeley, CA). She also collaborates with Cancer Targeted Technology, and her lab receives financial support in the form of a subcontract to a government small business grant from the National Cancer Institute (Bea Langton-Webster, PI). No other potential conflicts of interest were reported. Dr. Anderson is not an associate editor of manuscripts submitted to JNM with potential conflicts.
Ramsey D. Badawi, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is an investigator for United Imaging Healthcare. He also indicated that UC Davis has a revenue sharing agreement with United Imaging Healthcare. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.
Henryk Barthel, MD, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he has no potential conflicts of interest to report.
Frank M. Bengel, Associate Editor of The Journal of Nuclear Medicine, has indicated that he receives research funding from Siemens Healthineers and from GE Healthcare. He is also on the advisory board of Abbott and Pfizer and he receives speaker honoraria from GE Healthcare, Siemens Healthineers, Curium, Pfizer and Alnylam. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Lisa Bodei, Associate Editor of The Journal of Nuclear Medicine, has indicated that she is an unpaid consultant for AAA Novartis, Ipsen, Clovis Oncology and Curium. She also indicated that she is an unpaid speaker for AAA Novartis, Ipsen and ITM and has received research support from AAA Novartis. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.
Irene Buvat, Associate Editor of The Journal of Nuclear Medicine, has indicated that she is an unpaid consultant for Siemens Healthineers, GE Healthcare, and Dosisoft. She has received research support from Siemens Healthineers, GE Healthcare, and Dosisoft. She also indicated that she receives research support from the European Commission (H2020 programs), from INCA (French Institute of Cancer), and from ANR (French Research Agency). No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.
Marcelo F. DiCarli, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is an Investigator and has initiated and received institutional research grants from Gilead Sciences and Spectrum Dynamics. He also indicated that he receives consulting fees from Janssen and Bayer. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.
Michael M. Graham, PhD, MD, Associate Editor of TheJournal of Nuclear Medicine, has indicated that he has no potential conflicts of interest to report.
Jan Grimm, MD, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is a member of the scientific advisory board of LightPoint Medical without any financial interest or compensation. He also owns shares in NortisBio, a company in Seattle developing microfluidic chip systems for life sciences. He is a recipient of funding from the NIH.
Ken Herrmann, MD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is a board member of Sofie Biosciences; he holds equity in the company. He has also indicated that he holds equity in SurgicEye GmbH. He is on advisory boards and receives compensation and/or stock from AAA, ABX, Ipsen, BTG, Sirtex, Siemens Healthineers, Curium, Endocyte, and Theranostics Australia. No other potential conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.
Lale Kostakoglu, Associate Editor of The Journal of Nuclear Medicine, has indicated that she is a consultant for Roche and Genentech. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.
Jason S. Lewis PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is a co-founder and has equity in pHLIP, Inc. He is a co-Inventor on technology that has been licensed to Claymore Nanotechnologies LLC, Samus Therapeutics and Macrocyclics, Inc. He is on advisory boards and receives compensation and/or stock from Clarity Pharmaceuticals, Varian Medical Systems, Telix Pharmaceuticals Ltd., Fuzionaire, Inc., Fuzionaire Diagnostics, Inc. and Trace-Ability, Inc. His laboratory has received research support (financial and/or reagents) from Eli Lilly and Company, Sapience Therapeutics, Inc., Mabvax Therapeutics Holdings Inc., SibTech, Inc., Thermo Fisher Scientific, Ground Fluor Pharmaceuticals, Inc., ImaginAb, Inc. U.S., ContraFect Corporation, OncoQuest Inc., Merck & Company, Inc., AbbVie Inc., Bristol-Myers Squibb Company, Genentech, Inc., Y-mAbs Therapeutics, Inc., and Regeneron Pharmaceuticals, Inc. No other potential conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
David A. Mankoff, MD, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is a meeting participant/lecturer for Philips Medical. He is a part of a scientific study/trial for Siemens Medical. He is on advisory boards and receives compensation from GE Healthcare, Reflexion Medical, ImaginAb, and Blue Earth Diagnostics. He also receives investment interest from ImaginAb and Trevarx. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.
Heinrich Schelbert, MD, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he has no potential conflicts of interest to report.
Heiko Schoder, MD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is a consultant for Aileron Pharmaceuticals. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.
H. William Strauss, Associate Editor of The Journal of Nuclear Medicine, has indicated that he has no potential conflicts of interest to report.
Wolfgang Weber, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is on the advisory boards and receives compensation from Blue Earth Diagnostics, ITG and Pentixapharm. He has received research support from Blue Earth Diagnostics, BMS, Imaginab, Ipsen and Piramal. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.